The survival benefit was driven by a high rate of complete tumor regression in the combination treatment group compared with single-agent anti–PD-L1 (Supplemental Figure 13B; 7/11 vs. 3/11 mice, P < 0.05). The gene discussed is CD274; the disease is neoplasm.